SlidesetOncologyEvaluation of a physiological based pharmacokinetic model to evaluate the influence of covariates on sunitinib exposureView Slideset
SlidesetOncologyOptimal design – potential application in oncology drug development and clinical practice | Andrew Hooker, PhDView Slideset
SlidesetOncologyAssessment of the release of daunorubicin from liposomes after administration of daunoXome® using population pharmacokineticsView Slideset
SlidesetOncologyAssociation of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancerView Slideset
SlidesetOncologyPhysiologically based PK model vs. Population PK approach during drug development | Italo Poggesi, PhDView Slideset
SlidesetOncologyTrough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanomaView Slideset
SlidesetOncologyModeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimensView Slideset
SlidesetOncologyPK and PKPD considerations for dose selection in the development of pembrolizumab | Dinesh de Alwis, PhDView Slideset
